Curated coverage for immunotherapy with top developments, timeline context, and connected threads.
Personalized mRNA cancer vaccines showed 44% reduction in recurrence in melanoma trials. Here is when they will be available, who they will work for, and what the technology actually does.
EuroBulletin24 Editorial Desk | Linked source